Letter: lipid‐lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B—more evidence is needed
Alimentary Pharmacology & Therapeutics2017Vol. 46(8), pp. 769–770
Citations Over Time
Abstract
Linked Content This article is linked to Shaheen et al and Shaheen et al papers. To view these articles visit https://doi.org/10.1111/apt.14282 and https://doi.org/10.1111/apt.14218 .
Related Papers
- → 96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients(2022)21 cited
- → 21 TWO YEARS SAFETY AND EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH HBV-INDUCED CIRRHOSIS(2009)6 cited
- → 559 COST-EFFECTIVENESS SIMULATION ANALYSIS OF TENOFOVIR DISOPROXIL FUMARATE (TENOFOVIR) IN HBEAG NEGATIVE (-) PATIENTS WITH CHRONIC HEPATITIS-B (CHB) IN ITALY AND FRANCE(2008)6 cited
- → 20 THREE YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE AND POSITIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102 AND STUDY 103)(2010)1 cited
- → Tenofovir Disoproxil Fumarate Treatment for Pediatric Patients with Perinatally Acquired Chronic Hepatitis B(2015)1 cited